Clene Reports Second Quarter 2026 Financial Results and Recent Operating Highlights
Clene confirmed plans to submit a New Drug Application for CNM-Au8 in ALS under the accelerated approval pathway in early Q4 2026, following formal FDA confirmation of its filing ability. New biomarker analyses from completed Phase 2 trials showed that patients with declines or stabilization in neurofilament light (NfL) experienced significantly longer survival and better functional outcomes, supporting the regulatory submission. The company reported $9.7 million in cash as of June 30, 2026, with a net loss of $13.4 million for the quarter, and expects its current resources to fund operations into late Q4 2026.
Key figures
- Revenue
- 90000
- Net loss
- 13424000
- Ga expenses
- 1930000
- Rd expenses
- 3471000
- Burn rate 6m
- 7100000
- Cash balance
- 9671000
- Offering proceeds
- 7000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.